Talk:Infliximab

From Wikipedia, the free encyclopedia

Molecular and Cellular Biology WikiProject
MCB Portal
This article is within the scope of the Molecular and Cellular Biology WikiProject. To participate, visit the WikiProject for more information. The WikiProject's current monthly collaboration is focused on improving Restriction enzyme.

Article Grading: The article has not been rated for quality and/or importance yet. Please rate the article and then leave comments here to explain the ratings and/or to identify the strengths and weaknesses of the article. Click here for an overview of how to rate this article.
WikiProject Medicine This article is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at the doctor's mess.
B This page has been rated as B-Class on the quality assessment scale
High This article has been rated as High-importance on the importance assessment scale

Contents

[edit] This

http://www.reuters.com/newsArticle.jhtml?type=healthNews&storyID=6059613

This link is not good, it is in the article where the FDA gives a warning.

[edit] Cancer risk

Studies(published by the AMA) show that patients taking he rheumatoid arthritis drugs Remicade® (infliximab) or Humira® (adalimumab)have, on average, a three fold increased risk of developing cancer http://cancer.nchmd.org/news.aspx?id=36984 the study mentioned is:

Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serous infections and malignancies. Journal of the American Medical Association. 2006;295:2275-2285. —The preceding unsigned comment was added by 71.230.43.224 (talk) 04:17, 2 May 2007 (UTC).

[edit] Page merging

I see no reason to not merge the pages. --zandperl 02:22, 10 January 2006 (UTC)

These pages should definitely be merged; I'm currently on Remicade myself, and believe that the Infliximab article is a much more informative and thorough piece. --JamehTheBunneh 03:17, 12 January 2006 (UTC)

I deleted it. It was a clone. JFW | T@lk 18:15, 12 January 2006 (UTC)

[edit] Indications

I note that the indications are American -- they differ in other countries Barry Zuckerkorn 19:36, 24 January 2006 (UTC)

I miss the mention of Infliximab for the treatment of chronic uveitis and sarcoidosis. On patients websites for these diseases in both Europe and the United States you will find plenty of people following a succesfull long term treatment with Infliximab. Currently all medical insurance plans in the U.S. cover Infliximab for the treatment of sarcoidosis. There has also been a double blind randomised placebo controlled study on 137 sarcoidosis patients being treated with Infliximab. The study suggests a limited improvement in short term lung sarcoidosis patients and a significant improvement in patients with chronic refractory sarcoidosis. Types of extra pulmonary sarcoidosis like neurosarcoidosis seem to show the best reaction to the treatment.

For this comment I refer to the AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 174 2006

for infliximab and uveitis http://ard.bmj.com/cgi/content/abstract/66/4/548

patient websites:

groups.msn.com/sarcoidbuddies http://groups.msn.com/BesnierBoeckSarcoidose —Preceding unsigned comment added by 217.136.229.100 (talk) 15:02, 30 May 2008 (UTC)

[edit] Should Crohn's be considered an autoimmune condition

Crohn's does not represent the product of anti-self immunity.

[edit] high risk of tuberculosis

I miss the explicit warning for the high risk of reactivation of latent tuberculosis infection (LTBI), which is 5-10% in persons with LTBI on infliximab. Since the classical granuloma formation is absent the reactivation tuberculosis manifests itself in a severe disseminated form. Before startin infliximab screening for LTBI is needed. Persons from countries with a high tuberculosis prevalence need special attention. Sytze Keizer Tuberculosis Chest Physician, Amsterdam —The preceding unsigned comment was added by 212.123.200.82 (talk) 08:37, 23 March 2007 (UTC).

Absoluut. De vraag is of een Mantouxtest voldoende is, of dat er gescreend moet worden met interferon of ELISPOT. JFW | T@lk 14:42, 1 April 2007 (UTC)

TB: This is a class effect: An increased susceptibility to tuberculosis or reactivation of latent tuberculosis should be considered a class characteristic of TNF blocking agents. The clinical picture of latent tuberculosis may be atypical in these patients (for example, miliary or extrapulmonary presentations) as has been seen with other immunocompromised patients (category C evidence 177–179 181–183). There have been more reported cases of tuberculosis as a proportion of the total number of individuals treated in patients using infliximab and adalimumab than etanercept (category C evidence177–179 181 183 185). This may be due in part to the fact that populations treated with the various TNF blocking agents differ and the data come from registries and voluntary reporting systems. No head-to-head comparisons among TNF blocking agents have been done and thus no definitive data on comparisons between these agents are available regarding the incidence of reactivation of latent tuberculosis. infections have been treated adequately (category D evidence 177 180 182–184 187–190; FDA). D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, and M H Weisman Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 Ann Rheum Dis, Nov 2006; 65: iii2 - iii15

[edit] Should we have a section for controversies?

I was doing some research on the deceptive marketing practices of a different drug company and kept coming up with mentions of some pretty astounding deceptions used to market Remicade and/or get it to be a covered expense. I have no opinion on the drug one way or another but if you google the name and the wrod deceptive, you'll see what c omes up. These are well decumented events. I don't want to step in add a section of other frequent contributors feel it isn't warrented. I was merely surprised that no mention was made in the article of the C.A.R.E. Scam and the price-fixing scandal.LiPollis 10:52, 26 June 2007 (UTC)

[edit] IBS QOL

Improvement in many conditions is spectacular. In IBD, doi:10.1111/j.1572-0241.2007.01094.x suggests the HRQOL is persistently improved. JFW | T@lk 14:42, 1 April 2007 (UTC)

[edit] Broken refs

I put the word out to the original contributor to repair the broken refs, if possible. See User:Statesman 88#ACCENT1. MaxEnt (talk) 03:26, 5 December 2007 (UTC)